Novel Strategies for the Prediction and Control of Advanced Breast Cancer via nanoscaled Epigenetic-Based Biosensors

The first decade of the genomic era has identified key molecular subtypes in breast cancer, but these improvements in classification have not been translated into useful clinical practice. As such, the goal of our national collaboration is to translate new findings directly into the clinic, in order to create effective diagnostic devices that can operate in all pathology laboratories within and beyond Australia. To this end, over the past 3.5 years our existing NBCF consortium of oncologists, pathologists, epigeneticists and nanotechnologists have discovered more than 200 novel epigenetic changes that occur commonly in breast cancer.